close 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Change languageEesti
Ülevaade

UEC

13.5

+8.17%↑

UEC

13.5

+8.17%↑

UEC

13.5

+8.17%↑

UEC

13.5

+8.17%↑

UEC

13.5

+8.17%↑

Kodu・Aktsiate loetelu・Calumet Specialty Products Partners LP
Search

Calumet Specialty Products Partners LP

Avatud

SektorEnergia

0

Osta

Hinna uuendus 1. jaan 1970, 00:00 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad

By Trading Economics

Sissetulek

-351M

-37M

Müük

-39M

1B

Kasumimarginaal

-3.591

Töötajad

1,540

EBITDA

-273M

6.3M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-13.81% downside

Turustatistika

By TradingEconomics

Turukapital

1.3B

3B

Eelmine avamishind

0

Eelmine sulgemishind

0

Uudiste sentiment

By Acuity

50%

50%

65 / 137 Pingereas Energy

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

11.075 / N/A Toetus ja vastupanu

Calumet Specialty Products Partners LP Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. märts 2026, 23:31 UTC

Kuumad aktsiad

Stocks to Watch: Nike, RH, NCino

DJ

Loe

31. märts 2026, 22:35 UTC

Tulu

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

DJ

Loe

1. apr 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

DJ

Loe

31. märts 2026, 23:50 UTC

Omandamised, ülevõtmised, äriostud

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

DJ

Loe

31. märts 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

DJ

Loe

31. märts 2026, 23:33 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

DJ

Loe

31. märts 2026, 23:21 UTC

Tulu

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

DJ

Loe

31. märts 2026, 23:14 UTC

Market Talk
Tulu

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

DJ

Loe

31. märts 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

DJ

Loe

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Loss Widens >000002.SZ

DJ

Loe

31. märts 2026, 22:36 UTC

Tulu

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

DJ

Loe

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

DJ

Loe

31. märts 2026, 22:36 UTC

Tulu

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

DJ

Loe

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

DJ

Loe

31. märts 2026, 21:46 UTC

Omandamised, ülevõtmised, äriostud

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

DJ

Loe

31. märts 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

DJ

Loe

31. märts 2026, 21:35 UTC

Tulu

Nike Expects China Sales Down 20% in 4Q, CFO Says

DJ

Loe

31. märts 2026, 21:35 UTC

Tulu

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

DJ

Loe

31. märts 2026, 21:35 UTC

Tulu

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

DJ

Loe

31. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

DJ

Loe

31. märts 2026, 21:33 UTC

Tulu

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

DJ

Loe

31. märts 2026, 21:32 UTC

Tulu

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

DJ

Loe

31. märts 2026, 21:28 UTC

Tulu

Nike Expects to End 4Q With Elevated Inventory, CFO Says

DJ

Loe

31. märts 2026, 21:26 UTC

Tulu

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

DJ

Loe

31. märts 2026, 21:25 UTC

Tulu

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

DJ

Loe

31. märts 2026, 21:24 UTC

Market Talk
Tulu

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

DJ

Loe

31. märts 2026, 21:22 UTC

Tulu

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

DJ

Loe

31. märts 2026, 21:22 UTC

Tulu

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

DJ

Loe

31. märts 2026, 21:21 UTC

Tulu

Nike's Digital Channel Still Too Promotional, CFO Says

DJ

Loe

31. märts 2026, 21:20 UTC

Tulu

Nike CEO: Converse Remains Important to Portfolio

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Calumet Specialty Products Partners LP Prognoos

Hinnasiht

By TipRanks

-13.81% langus

12 kuu keskmine prognoos

Keskmine 30.2 USD  -13.81%

Kõrge 34 USD

Madal 25 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Calumet Specialty Products Partners LP 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

3

Osta

3

Hoia

0

Müü

Põhineb 6 analüütiku instrumendi Calumet Specialty Products Partners LP aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

11.075 / N/AToetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Bullish events outweigh bearish events.

Keskpikk perspektiiv

Weak Bearish Evidence

Bearish events outweigh bullish events.

Pikk perspektiiv

Strong Bearish Evidence

All events are bearish.

Sentiment

By Acuity

65 / 137 Pingereas Energia

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Calumet Specialty Products Partners LP

Calumet, Inc. manufactures, formulates, and markets a diversified slate of specialty branded products and renewable fuels to various consumer-facing and industrial markets in North America and internationally. It operates through Specialty Products and Solutions; Montana/Renewables; and Performance brands segments. The Specialty Products and Solutions segment offers various solvents, waxes, customized lubricating oils, white oils, petrolatums, gels, esters, and other products. The Montana/Renewables segment focuses on processing renewable feedstocks into renewable diesel, sustainable aviation fuel, renewable hydrogen, renewable natural gas, renewable propane, and renewable naphtha. It also processes Canadian crude oil into conventional gasoline, diesel, jet fuel, and specialty grades of asphalt. The Performance Brands segment blends, packages, and markets high performance products through Royal Purple, Bel-Ray, and TruFuel brands. The company serves wholesale distributors and retail chains. Calumet, Inc. was founded in 1919 and is headquartered in Indianapolis, Indiana.

Muud aktsiad sektorist

UEC

Uranium Energy Corp

13.5

↑ +8.17%
help-icon Live chat